New Hope in
Fighting XDR-TB
[Posted 02/27/2009]
Research by Albert Einstein College of Medicine and
National Institute of Allergy and Infectious
Diseases provides new hope in treating extensively
drug-resistant tuberculosis (XDR-TB).
A combination of two FDA-approved drugs (clavulanate
and meropenem) has been shown to be effective not
only in treating TB, but also in inhibiting the
growth of 13 XDR-TB strains.
The
study was published in the February 27 issue of
Science.
Related Links:
Science Abstract
Healthfinder News Article
Go to News
Summary Page:
Health-related News Summaries